Menu
Not yet recruiting NCT03244072

Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery

Phase II / Phase III Interventional Endophthalmitis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Moxifloxacin, Placebo.
Who it may be relevant to
Registry conditions: Endophthalmitis. Basic parameters: from 40 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Safety and Efficacy of Intracameral Zimoxin (0.1% Moxifloxacin Solution) for Prevention of Endophthalmitis After Cataract Surgery

Overview

Intracameral injection of 0.1% moxifloxacin solution after cataract surgery to prevent endophthalmitis

Detailed description

Subjects will receive either intracameral injection of 0.1% moxifloxacin solution or placebo after cataract surgery. They will be followed for one month to determine if there is a statistically significant difference in the incidence of endophthalmitis.

Interventions

  • Drug Moxifloxacin
    Intracameral injection
  • Drug Placebo
    intracameral injection

Primary outcome measures

  • Endophthalmitis after cataract surgery [Time frame: Subjects will undergo eye examinations at one day, one week, and one month post-operatively]

Eligibility criteria

Inclusion criteria

  • visually significant cataracts

Exclusion criteria

  • allergy to fluoroquinolones, cobalamin (B12)

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Triple blind
Primary purpose
Prevention

Study locations

United States · 1 center
  • Zion Eye Institute — St. George

Identifiers

NCT: NCT03244072 · PIND 134134

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗